To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

[AI summary unavailable — showing source text] [Congressional Bills 118th Congress] [From the U.S. Government Publishing Office] [H.R. 5850 Introduced in House (IH)] <DOC> 118th CONGRESS 1st Session H. R. 5850 To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES September 29, 2023 Mr. Mann (for himself and Mr. Moolenaar) introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. NULLIFICATION OF REMS MODIFICATIONS FOR MIFEPRISTONE; NO FEDE…